Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: majormember who wrote (460)	3/12/1998 10:36:00 PM
From: Mack Earnhardt	Read Replies (3) \| Respond to of 4140

How much does anyone here know about potential competition? This is a little dated, but I just noticed this paragraph in a VISX release: Mark Logan, VISX chairman and chief executive officer, said, ''This is another step in our ongoing efforts to offer U.S. doctors and consumers the same range of procedures as their international counterparts. Not only is VISX the first and only company in the U.S. to receive approval for the treatment of low, moderate and high myopia with astigmatism, but we also expect to file for approval of hyperopia (farsightedness) in the first quarter. The broad beam and scanning capabilities of the advanced VISX STAR are proving invaluable as we move to have additional indications approved by the FDA.'' The full text is at: biz.yahoo.com I should mention just for the record that I am long in both SNRS and VISX. The SNRS procedure has a definite edge on farsightedness from what I've read here and elsewhere, but they may not be the only fish in the pond. Does anyone have any information or thoughts on this. How many companies are working on this and who will be first to get approval? -Mack